New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAICAR vs Cagrilintide

AICAR vs Cagrilintide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & LongevityFat Loss & Metabolic
AICAR
GLP-1 / Weight Loss Agonists
Cagrilintide
Summary
AICAR is a cell-permeable AMP analog that activates AMPK (AMP-activated protein kinase) — the master metabolic switch that triggers fat burning, mitochondrial biogenesis, and adaptations normally only achieved through exercise. It has been called the 'exercise in a pill' compound.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
Half-Life
~2–3 hours
~7–10 days
Admin Route
SubQ, IV
SubQ
Research
Typical Dose
25–50 mg
0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
Frequency
3–5 times per week
Once weekly
Key Benefits
  • AMPK activation mimics aerobic exercise adaptations
  • Increased fat oxidation and endurance
  • Mitochondrial biogenesis (PGC-1alpha)
  • Improved insulin sensitivity and glucose metabolism
  • Anti-inflammatory effects
  • Potential cardiac protection during ischemia
  • Synergistic with actual exercise training
  • Reduces hepatic glucose production
  • ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
  • Synergistic appetite suppression complementing GLP-1 receptor agonists
  • Reduces post-meal glucagon excursions improving glycemic control
  • Slows gastric emptying contributing to prolonged satiety
  • Once-weekly dosing via subcutaneous injection
  • Potential for greater weight loss than semaglutide monotherapy
Side Effects
  • Hypoglycemia risk
  • Lactic acidosis at high doses (animal data)
  • Injection site irritation
  • Nausea (most common, especially during titration)
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +2 more
Stacks With